Adamis Pharmaceuticals changes its name to DMK Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation a commercial-stage biopharmaceutical company, announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders
In conjunction with the name change, the company’s common stock is expected to trade under the new Nasdaq ticker symbol “DMK” on or about September 8, 2023. The CUSIP number for the common stock, 00547W307, will remain unchanged.
Despite their almost identical names; Adamis Pharmaceuticals and Adamas Pharmaceuticals are both totally separate companies, based at opposite ends of California.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins